A review published in European Urology Focus looks at tools to optimise the choice and sequence of treatments to ensure the best clinical benefit for their metastatic renal cell carcinoma (RCC) patients. The review concludes that the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model is currently the only validated tool that can help clinicians decide which patients should receive sunitinib versus a combination of nivolumab and ipilimumab as a first treatment for metastatic RCC. Other tools are being actively investigated in clinical trials.
Predictive biomarkers in metastatic kidney cancer
23 May 2019
biological markers
biomarkers
IMDC
ipilimumab
nivolumab
Opdivo
renal cell carcinoma
sunitinib
Sutent
Yervoy
Kidney cancer news
20 Mar 2023
Adjuvant nivolumab plus ipilimumab for localised kidney cancer
20 Mar 2023
Fat loss may result in worse outcomes for patients treated with immunotherapy for metastatic kidney cancer
16 Mar 2023
Results from a phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of kidney cancer
16 Mar 2023
Improved health-related quality of life using a mindfulness app for kidney cancer patients
16 Mar 2023
How time of day of immunotherapy infusion affects kidney cancer outcomes
15 Mar 2023
Benefits persist for lenvatinib plus pembrolizumab in advanced kidney cancer
9 Mar 2023
TKI treatment breaks may not affect outcomes in kidney cancer
7 Mar 2023
ASCO GU 20023: Cabozantinib as a second-line treatment for patients with advanced kidney cancer
7 Mar 2023
ASCO GU 2023: A triple combination for previously untreated kidney cancer patients
6 Mar 2023
ASCO GU 2023: Treatment-free survival for advanced kidney cancer patients on nivolumab and salvage nivolumab/ipilimumab
6 Mar 2023
Savolitinib plus durvalumab for papillary kidney cancer
27 Feb 2023
Genes reveal risk of recurrence of kidney cancer
Most used tags
renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib Sutent progression-free survival cabozantinib biomarkers NHS England Cabometyx ipilimumab COVID-19 pembrolizumab cancer survival axitinib VEGF inhibitors non-clear cell kidney cancer Inlyta coronavirus Yervoy risk factors Keytruda metastases adjuvant therapy biological markers targeted therapy papillary RCC everolimus Afinitor ASCO cancer outcomes first-line treatment NICE partial nephrectomyArchives
- 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
